Cargando…
Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia
Background: Phosphoinositide 3-kinase inhibitors (PI3Ki) are a new class of medications used to treat HR positive, HER2 negative, PIK3CA mutated advanced or metastatic breast cancer. Inhibition of PI3K, a key enzyme in the insulin signaling pathway, leads to disruption of glucose metabolism and freq...
Autores principales: | Shey, Susan, Kim, Sarah, Kim, Julie, Murphy, Elizabeth J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089671/ http://dx.doi.org/10.1210/jendso/bvab048.803 |
Ejemplares similares
-
MON-LB128 Phosphoinositide 3-Kinase (PI3K) Inhibitor Induced Hyperglycemia With Alpelisib
por: Barsukova, Yuliya, et al.
Publicado: (2020) -
Alpelisib-Induced Hyperglycemia- A Small Case Series
por: Ekanayake, Preethika Subashini, et al.
Publicado: (2021) -
Hyperglycemia-Induced Metabolic Reprogramming Mediates a Proatherogenic Phenotype in Healthy Human Monocytes
por: Castro-Grattoni, Anabel Lourdes, et al.
Publicado: (2021) -
SUN-163 Implementation of a Protocol for the Management of Steroid-Induced Hyperglycemia
por: Khan, Mahmuda, et al.
Publicado: (2019) -
MON-650 Glucocorticoid- Induced Hyperglycemia, Higher Mortality and Morbidity? a Retrospective Analysis
por: Delfs, Neele, et al.
Publicado: (2020)